Physiological capacity of the reticuloendothelial system for the degradation of hemoglobin vesicles (artificial oxygen carriers) after massive intravenous doses by daily repeated infusions for 14 days

Hiromi Sakai, Yohei Masada, Hirohisa Horinouchi, Eiji Ikeda, Keitaro Sou, Shinji Takeoka, Makoto Suematsu, Masuhiko Takaori, Koichi Kobayashi, Eishun Tsuchida

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

A hemoglobin vesicle (HbV; diameter 252 ± 53 nm) or liposome-encapsulated Hb is an artificial oxygen carrier developed for use as a transfusion alternative, and its oxygen-transporting capacity has been well characterized, although critical physiological compartments for the Hb degradation after a massive infusion of HbV and the safety outcome remain unknown. In this study, we aimed to examine the compartments for its degradation by daily repeated infusions (DRI) of HbV, focusing on its influence on the reticuloendothelial system (RES). Male Wistar rats intravenously received the HbV suspension at 10 ml/kg/day for 14 consecutive days. The cumulative infusion volume (140 mi/kg) was equal to 2.5 times the whole blood volume (56 mi/kg). The animals tolerated the DRI well and survived, and body weights continuously increased. One day after DRI, hepatosplenomegaly occurred significantly through the accumulation of large amounts of HbV. Plasma clinical chemistry was overall normal, except for a transient elevation of lipid components derived from HbV. These symptoms subsided 14 days after DRI. Hemosiderin deposition and up-regulation of heme oxygenase-1 coincided in the liver and spleen but were not evident in the parenchyma of these organs. Furthermore, the plasma iron and bilirubin levels remained unchanged, suggesting that the heme-degrading capacity of the RES did not surpass the ability to eliminate bilirubin. In conclusion, phospholipid vesicles for the encapsulation of Hb would be beneficial for heme detoxification through their preferential delivery to the RES, a physiological compartment for degradation of senescent RBCs, even at doses greater than putative clinical doses.

Original languageEnglish
Pages (from-to)874-884
Number of pages11
JournalJournal of Pharmacology and Experimental Therapeutics
Volume311
Issue number3
DOIs
Publication statusPublished - 2004 Dec

Fingerprint

Blood Substitutes
Mononuclear Phagocyte System
Oxygen
Heme
Bilirubin
Hemosiderin
Clinical Chemistry
Heme Oxygenase-1
Blood Volume
Liposomes
Wistar Rats
Phospholipids
Suspensions
Hemoglobins
Up-Regulation
Spleen
Iron
Body Weight
Lipids
Safety

ASJC Scopus subject areas

  • Pharmacology

Cite this

Physiological capacity of the reticuloendothelial system for the degradation of hemoglobin vesicles (artificial oxygen carriers) after massive intravenous doses by daily repeated infusions for 14 days. / Sakai, Hiromi; Masada, Yohei; Horinouchi, Hirohisa; Ikeda, Eiji; Sou, Keitaro; Takeoka, Shinji; Suematsu, Makoto; Takaori, Masuhiko; Kobayashi, Koichi; Tsuchida, Eishun.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 311, No. 3, 12.2004, p. 874-884.

Research output: Contribution to journalArticle

Sakai, Hiromi ; Masada, Yohei ; Horinouchi, Hirohisa ; Ikeda, Eiji ; Sou, Keitaro ; Takeoka, Shinji ; Suematsu, Makoto ; Takaori, Masuhiko ; Kobayashi, Koichi ; Tsuchida, Eishun. / Physiological capacity of the reticuloendothelial system for the degradation of hemoglobin vesicles (artificial oxygen carriers) after massive intravenous doses by daily repeated infusions for 14 days. In: Journal of Pharmacology and Experimental Therapeutics. 2004 ; Vol. 311, No. 3. pp. 874-884.
@article{455ad0015a1b48459e45f6c3238d38d5,
title = "Physiological capacity of the reticuloendothelial system for the degradation of hemoglobin vesicles (artificial oxygen carriers) after massive intravenous doses by daily repeated infusions for 14 days",
abstract = "A hemoglobin vesicle (HbV; diameter 252 ± 53 nm) or liposome-encapsulated Hb is an artificial oxygen carrier developed for use as a transfusion alternative, and its oxygen-transporting capacity has been well characterized, although critical physiological compartments for the Hb degradation after a massive infusion of HbV and the safety outcome remain unknown. In this study, we aimed to examine the compartments for its degradation by daily repeated infusions (DRI) of HbV, focusing on its influence on the reticuloendothelial system (RES). Male Wistar rats intravenously received the HbV suspension at 10 ml/kg/day for 14 consecutive days. The cumulative infusion volume (140 mi/kg) was equal to 2.5 times the whole blood volume (56 mi/kg). The animals tolerated the DRI well and survived, and body weights continuously increased. One day after DRI, hepatosplenomegaly occurred significantly through the accumulation of large amounts of HbV. Plasma clinical chemistry was overall normal, except for a transient elevation of lipid components derived from HbV. These symptoms subsided 14 days after DRI. Hemosiderin deposition and up-regulation of heme oxygenase-1 coincided in the liver and spleen but were not evident in the parenchyma of these organs. Furthermore, the plasma iron and bilirubin levels remained unchanged, suggesting that the heme-degrading capacity of the RES did not surpass the ability to eliminate bilirubin. In conclusion, phospholipid vesicles for the encapsulation of Hb would be beneficial for heme detoxification through their preferential delivery to the RES, a physiological compartment for degradation of senescent RBCs, even at doses greater than putative clinical doses.",
author = "Hiromi Sakai and Yohei Masada and Hirohisa Horinouchi and Eiji Ikeda and Keitaro Sou and Shinji Takeoka and Makoto Suematsu and Masuhiko Takaori and Koichi Kobayashi and Eishun Tsuchida",
year = "2004",
month = "12",
doi = "10.1124/jpet.104.073049",
language = "English",
volume = "311",
pages = "874--884",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Physiological capacity of the reticuloendothelial system for the degradation of hemoglobin vesicles (artificial oxygen carriers) after massive intravenous doses by daily repeated infusions for 14 days

AU - Sakai, Hiromi

AU - Masada, Yohei

AU - Horinouchi, Hirohisa

AU - Ikeda, Eiji

AU - Sou, Keitaro

AU - Takeoka, Shinji

AU - Suematsu, Makoto

AU - Takaori, Masuhiko

AU - Kobayashi, Koichi

AU - Tsuchida, Eishun

PY - 2004/12

Y1 - 2004/12

N2 - A hemoglobin vesicle (HbV; diameter 252 ± 53 nm) or liposome-encapsulated Hb is an artificial oxygen carrier developed for use as a transfusion alternative, and its oxygen-transporting capacity has been well characterized, although critical physiological compartments for the Hb degradation after a massive infusion of HbV and the safety outcome remain unknown. In this study, we aimed to examine the compartments for its degradation by daily repeated infusions (DRI) of HbV, focusing on its influence on the reticuloendothelial system (RES). Male Wistar rats intravenously received the HbV suspension at 10 ml/kg/day for 14 consecutive days. The cumulative infusion volume (140 mi/kg) was equal to 2.5 times the whole blood volume (56 mi/kg). The animals tolerated the DRI well and survived, and body weights continuously increased. One day after DRI, hepatosplenomegaly occurred significantly through the accumulation of large amounts of HbV. Plasma clinical chemistry was overall normal, except for a transient elevation of lipid components derived from HbV. These symptoms subsided 14 days after DRI. Hemosiderin deposition and up-regulation of heme oxygenase-1 coincided in the liver and spleen but were not evident in the parenchyma of these organs. Furthermore, the plasma iron and bilirubin levels remained unchanged, suggesting that the heme-degrading capacity of the RES did not surpass the ability to eliminate bilirubin. In conclusion, phospholipid vesicles for the encapsulation of Hb would be beneficial for heme detoxification through their preferential delivery to the RES, a physiological compartment for degradation of senescent RBCs, even at doses greater than putative clinical doses.

AB - A hemoglobin vesicle (HbV; diameter 252 ± 53 nm) or liposome-encapsulated Hb is an artificial oxygen carrier developed for use as a transfusion alternative, and its oxygen-transporting capacity has been well characterized, although critical physiological compartments for the Hb degradation after a massive infusion of HbV and the safety outcome remain unknown. In this study, we aimed to examine the compartments for its degradation by daily repeated infusions (DRI) of HbV, focusing on its influence on the reticuloendothelial system (RES). Male Wistar rats intravenously received the HbV suspension at 10 ml/kg/day for 14 consecutive days. The cumulative infusion volume (140 mi/kg) was equal to 2.5 times the whole blood volume (56 mi/kg). The animals tolerated the DRI well and survived, and body weights continuously increased. One day after DRI, hepatosplenomegaly occurred significantly through the accumulation of large amounts of HbV. Plasma clinical chemistry was overall normal, except for a transient elevation of lipid components derived from HbV. These symptoms subsided 14 days after DRI. Hemosiderin deposition and up-regulation of heme oxygenase-1 coincided in the liver and spleen but were not evident in the parenchyma of these organs. Furthermore, the plasma iron and bilirubin levels remained unchanged, suggesting that the heme-degrading capacity of the RES did not surpass the ability to eliminate bilirubin. In conclusion, phospholipid vesicles for the encapsulation of Hb would be beneficial for heme detoxification through their preferential delivery to the RES, a physiological compartment for degradation of senescent RBCs, even at doses greater than putative clinical doses.

UR - http://www.scopus.com/inward/record.url?scp=10044298332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10044298332&partnerID=8YFLogxK

U2 - 10.1124/jpet.104.073049

DO - 10.1124/jpet.104.073049

M3 - Article

C2 - 15297471

AN - SCOPUS:10044298332

VL - 311

SP - 874

EP - 884

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 3

ER -